华森制药：获得药物临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its self-developed drug CX001 sustained-release tablets, aimed at treating postherpetic neuralgia [1] Group 1: Drug Development - The drug CX001 is classified as a chemical drug of category 2.2 and is designed as a sustained-release tablet [1] - The clinical trial is specifically for the indication of treating postherpetic neuralgia [1] - The sustained-release formulation is expected to reduce dosing frequency, enhance patient compliance, and improve sleep quality [1]